Dupilumab is a Predominant Treatment for Recalcitrant Bullous Pemphigoid. ACCR [Internet]. 2021 Feb. 24 [cited 2026 Sep. 14];4(1):1-4. Available from: https://somatopub.com/index.php/ACCR/article/view/17